濠电姷顣藉Σ鍛村磻閹捐泛绶ゅΔ锝呭暞閸嬪鏌eΟ娆惧殭鏉╂繈姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倸鍊烽懗鑸电仚濡炪倖鍨甸幊鎰板箲閵忋倕绠i柨鏇楀亾闁藉啰鍠栭弻銊╂偆閸屾稑顏� 闂傚倸鍊烽懗鑸电仚缂備胶绮〃鍛存偩閻戣姤鍋ㄧ紒瀣閻庮剟姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倸鍊峰ù鍥ㄧ珶閸惊娑㈠礋椤栤偓閸ヮ剙绀冮柤纰卞墯濞堝ジ姊虹捄銊ユ珢闁瑰嚖鎷� 缂傚倸鍊搁崐椋庣矆娓氣偓閹鎳栭埡鍌氬簥濠电娀娼ч悧蹇曠矆婵犲洦鐓ラ柣鏇炲€圭€氾拷 闂傚倸鍊风粈渚€骞栭锕€纾瑰┑鐘宠壘缁犵娀鏌熼幆褏鎽犳繛鍛█閺屻劑鎮ら崒娑橆伓 濠电姷鏁搁崑鐐哄垂鐠轰綍娑㈠箣閻愭壆绠氶梺鎼炲労閸撴岸宕曢幘缁樼叆闁绘洖鍊圭€氾拷 濠电姷鏁搁崑鐐哄垂閸洖绠归柍鍝勬噹閻鏌嶈閸撴盯鍩€椤掑喚娼愰柟纰卞亰楠炲繘鏁撻敓锟� 闂傚倷娴囧畷鐢稿窗閹扮増鍋¢柕澶堝剻濞戞ǚ鏀介悗锝冨妷閸嬫捇宕掗悙瀛樻闂佽法鍣﹂幏锟�

缂傚倸鍊搁崐椋庣矆娓氣偓钘濋柟宄版湰閹冲矂姊绘担鍛婃儓闁活剙銈稿畷浼村冀瑜滈崵鏇㈡煕婵犲嫬鏋旈柣銈傚亾闂備礁鎼ú銊╁窗閹剧粯鍋橀柕澶嗘櫆閳锋垿鏌熺粙鍧楊€楅柛鐘虫礋閺岀喖宕欓妶鍡楊伓 闂傚倸鍊风粈渚€骞夐敓鐘茬闁哄洢鍨圭粻鐘绘煙閺夊灝绨荤紓宥嗙墵閺屻劑鎮ら崒娑橆伓 濠电姷鏁告慨浼村垂婵傜ǹ鏄ラ柡宥庡幗閸嬪绻濇繝鍌滃⒊缂傚秵鐗犻弻銊╂偆閸屾稑顏� 濠电姷鏁告慨鐑姐€傛禒瀣劦妞ゆ帒鍟悵顏嗏偓鐟版啞缁诲啴濡甸崟顖f晝妞ゆ帊绀侀锟� 闂傚倸鍊烽悞锕傛儑瑜版帒鍨傚ù鐘茬懁婢舵劕绠诲ù鍏肩懅缁嬪繘姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倸鍊风粈渚€骞夐敓鐘冲仭闂侇剙绉寸粻顖炴煥閻曞倹瀚� 闂傚倸鍊风粈渚€骞楀⿰鍕灁闁圭虎鍠栫粻顖炴煥閻曞倹瀚� 濠电姵顔栭崰妤€鐣烽崹顕呭悑闁糕剝顨忔导锟� 闂傚倸鍊烽悞锕€顪冮幐搴n洸闁绘垼妫勭粻顖炴煥閻曞倹瀚� 闂傚倸鍊烽懗鍫曞储瑜庨幆鏂库堪閸繄顔嗛梺璺ㄥ櫐閹凤拷 闂傚倸鍊烽懗鑸电仚濠殿喗锕粻鎴﹀煝閺冨牆鍗虫い顐枤缁嬪繘姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倸鍊峰ù鍥ㄧ珶閸澀鐒婃繛鍡樺姈閸欏繐螖閿濆懎鏆欑痪鎯ф健閺屻劑鎮ら崒娑橆伓 婵犵數濮烽弫鎼佸磻濞戔懞鍥敍閻愭潙娈e銈嗙墬缁海绮堥崟顖涚叆闁绘洖鍊圭€氾拷 闂傚倸鍊烽懗鍫曞储瑜嶉锝夊礈娴g懓搴婇梺绯曞墲缁嬫垹澹曢崸妤佺叆闁绘洖鍊圭€氾拷 闂傚倸鍊烽懗鍫曞储瑜嶉锝夊礈娴h櫣鐓撻梺鍝勭▉閸樿偐澹曟繝姘叆闁绘洖鍊圭€氾拷 濠电姴鐥夐弶搴撳亾濡や焦鍙忓ù鍏兼綑缁€澶愬箹閹碱厾鍘滅紓宥嗙墵閺屻劑鎮ら崒娑橆伓 缂傚倸鍊搁崐宄邦渻閹烘鍤勯柛顐f礀绾惧鏌i弬鎸庢儓闁搞劍绻堥弻銊╂偆閸屾稑顏� 闂傚倸鍊风粈渚€骞夐敍鍕煓闁规崘顕ч崒銊ф喐閺冨牏宓侀柛鈩冪⊕閺呮悂鏌ㄩ悤鍌涘 闂傚倸鍊烽悞锕€顪冮崸妤佸亗闁割偁鍎辩粣妤佺箾閹存瑥鐏╃痪鎯ь煼閺屻劑鎮ら崒娑橆伓 闂傚倸鍊峰ù鍥ㄧ珶閸澀鐒婃い蹇撳閺嬫牠鏌¢崶鈺佲偓锝夋晲婢跺娅㈤梺璺ㄥ櫐閹凤拷 缂傚倸鍊搁崐鎼佸磹缁嬫5娲Χ閸♀晜顔旈梺褰掓?缁讹繝寮繝鍥ㄧ叆闁绘洖鍊圭€氾拷 婵犵數濮烽弫鍛婃叏閹绢喗鏅濋柕鍫濐樈閺佸嫰鏌涢顒傜ɑ闁挎冻鎷� 闂備浇顕уù鐑藉磻閿濆纾规繛鎴炃氶弸鏍ㄧ箾閹存瑥鐒洪柡浣割儔閺屻劑鎮ら崒娑橆伓 闂傚倸鍊搁オ鎾磻閸曨個娲Χ婢跺﹦鏌堥梺瑙勫劶濡嫮绮堥崼銉︾叆闁绘洖鍊圭€氾拷 濠电姷顣槐鏇㈠磻濞戙埄鏁勯柛銉墮缁愭鏌熼幑鎰靛殭闁告垹濞€閺屻劑鎮ら崒娑橆伓 闂傚倸鍊风粈浣革耿鏉堛劎浠氭俊鐐€х紓姘跺础閹剁晫宓佸┑鐘叉处閺呮悂鏌ㄩ悤鍌涘 婵犵數濮烽弫鎼佸磻濞戙垺鍎旈柤娴嬫櫅閸ㄦ繃銇勯弽顐粶闁藉啰鍠栭弻锝夊籍閸嬪啿婀卞▎銏ゆ倷閸偄鏋戦悗骞垮劚椤︻垶鎯屽Δ鍛叆闁绘洖鍊圭€氾拷
您所在的位置:首页 > 医学书籍 > 其它科目 > 动脉粥样硬化
第四节 HMGCoA还原酶
http://www.xxmy.com  2005-3-1 23:11:58 董学梅]  【字体:
缂佽妞掔紞瀣偋閿燂拷

第四节 HMGCoA还原酶

  HMGCoA还原酶(HMGCoa reductase)是胆固醇合成的限速酶,存在于小胞体膜,催化合成甲基二羟戊酸(mevalonic acid),并生成体内多种代谢产物,称之为甲基二羟戊酸途径。细胞内胆固醇水平调节主要信赖于内因性胆固醇合成途径和LDL受体摄取细胞外胆固醇的外因途径两条。Goldstein ,Brown阐明其抑制机制认为,细胞内ch作为HMGCoA还原酶抑制剂使其活性降低,肝细胞膜上的LDL受体增加,从血中摄取ch增加,使血中胆固醇水平降低,设想HMGCoA还原酶活性降低的药物可使血中胆固醇水平下降,尤其是对FH的杂合子患者,LDL受体数锐减者可起治疗作用。

  Kovanen等报导以merinolin的HMGCoA还原酶抑制剂投入,使狗血中LDL消失速度上升,LDL产生速度下降,肝移植的小儿FH纯合子患者,用梅维诺林治疗可使LDL胆固醇降低40%,而LDL产生速度下降35%,LDL合成减少的机制,有两种可能,一是胆固醇合成减少使VLDL生成量降低;第二是HMGCoA还原酶抑制剂使VLDL残粒或βVLDL异化增加,转变成LDL减少,体外实验也证实,从VLDL残粒到LDL的速度比正常状态下小20倍,与此同时LDL受体的亲和力也增加。

  仓鼠HMGCoA还原酶基因长30kb,由20个外显子组成,在启动子5'端富含GC碱基。HMGCoA还原酶,从转录水平作为胆固醇代谢的调节点,与LDL受体基因启动子,HMGCoA合成酶,从转录调节域存在有相同的碱基系列,即CACCCC(或GT)AC的胆固醇调节元件(sterol regulatory element,SRE)存在,如图5-5所示。

图5-5 胆固醇代谢调节的启动子与SRE

  第一条线的数字为从转录开始的距离(碱基对数)

(董学梅)

  参 考 文 献

  1.杨振华,酶的测定,见:叶应妩,李健斋,王玉琛主编。临床实验诊断学,北京:人民卫生出版社,1991,588~466

  2.Paltarf F,Wagner E,Stereospecificity of Lipase enzymatic hydrolyosis of enantiomeric aldyldiacyl and dialdylacylglyerols by lipoprotein lipase.Biochim Biophys Acta,1976,431:359-362

  3.Deeb SS.Peng R.Structure of the human lipoprotein lipase gene .Biochemistry,1989,1169:582-4134

  4.Gotoda T,et al.Anewly identified null allelic mutation in the human lipoprotein lipase(LPL)gene of a compornd heterozygote with familial LPL deficienacy,Biochys Acta,1992,1169:582-586

  5.Okabe T,Yorifaji H,et al .Pulmonary macrophage:Amajor source of lipoprtein lipase in the lung.Biochim Biophys Res Commun,1984,125:273-278

  6.Oka K,George T,Stocks J,et al.Nucleotide sequence of PvuⅡpoolymorphic site at the human lipoprotein lipase gene locus .Nuceic Acids Research,1990,18:5407-5411

  7.Chuat J,Raisonnier A,Etienne J,et al.The lipoprotein lipase-encodigng human gene:sequence from intron-6 to intron-9 and presence in intron-7 of a 40-million-year-old Alu sequence.Gene,1992,110:257-261

  8.Gotoda T,Yamada N,Murase T,et al .Detection of three separate DNA polymorphisms in the human lipoprotein lipase gene by gene amplfication and restriction endonuclease digestion.J Lipid Res,1992,33:1067-1072

  9.Raj K,Edward W,Ruth M,et al .DNA variants at the LPLgene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a welsh poprlation.Arteriosclerosis and Thrombosis,1994,14:1090-1097

  10.Robert A,Andrew J,Liling T,et al .Agene-gender interaction affecting plasma lipoproteins in a genetic isoalate,Arteriosclerosis and Thrombosis,1994,14671-677

  11.Yang C,et al.Lecithin:cholesterol acyltransferase.J Biol Chem,1987,262:3086-3091

  12. Alberts J,Adolphson J,Chen C,et al.Radiommunoassay of human plasma lecithin cholesterol acyltransferase.J Clin Invest,1981,67:141-148

  13.Mclean J et al .Cloning and expression of human lecithin cholesterol transferase cDNA ,Proc Natl Acad Sci USA ,1986,83:2335-2339

  14.Glomset .J.Norum K,Gjone E,et al.Lecithin:cholesterol acyltransferase deficiency.In:The Metabolic Basis of Inherited Disease.McGraw Hill ,New Youk,1983,643-654

  15.Glomset J.The plama lecithin cholesterol acyltransferase reaction.J Lipid Res,1968,9:156-167

  16.Holmqusit Z,Carlson L.Normalization of high density lipoprotein in fish eye disease plasma by purified normal human lecithin cholesterol acyltransferase .Lipids ,1988,23:225-229

  17.Zilversmit D B.Atherogenic nature of triglycerides .postprandial lipidemia and triglyceride-rich remnant.Clin Chem,1995,41:153-158

  18.Takagi A, et al.Molecular strdies on primary lipoprotein lipase(LPL)deficiency:one base deltion (G916)in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPLmessenger RNA transcript.Jclin Invest,1992,41:153-158

  19.Jingami R,Brown M,Goldstein J,et al .Partial deletion of membrane-bound domain of 3-hydroxy-3methylglu-taryl coenzyme a reductase eliminates sterol enhanced degradation and prevents formation of crystalloid endoplasmic reticulum,Jcell Biol,1987,104:1693

  20.Goldsteir J,Brown M,Regulation of the mevalonate pathway.Nature ,1990,343:425-430

  21.East C,Grundy S,Bilheimer D,et al.Preliminary report:Treatment of ytpe 3 hyperlipidemia with mevinolin.Metabolism,1986,35:97098-,104:1693

  22.阵上久人,HMGCoa Reductaseとそのinhibiter .最新医学,1992,47:82-90

  

页面功能 【参与评论】【收藏此文】【打印文章】【网上投稿关闭窗口
上一编:第六章 脂蛋白受体-<BR>-第一节 低密度脂蛋白受体
下一编:第三节 卵磷脂胆固醇酯酰转移酶
...........

栏目列表


Copyright © 2016闂備線娼уΛ宀勫磻閹兼獰my.com闂備線娼уΛ宀勫磻閹讳康l rights reserved. 闂備胶绮〃鍛存偋婵犲倴缂氶柛顐犲劚缁犮儵鏌嶈閸撶喎顕i悽鍛婃櫢闁跨噦鎷� 濠电偞鍨堕幖鈺呭储閼测晙鐒婇柣妤€鐗忛埢鏃€銇勯幘顖楀亾瀹曞洢鍋愮紓鍌欑椤︽媽鎽梺鍝勭灱閸犳挾妲愰弮鍫熸櫢闁跨噦鎷� 闂備礁鎼悧婊堝礈濞戙垺鍋熸い鏍ㄥ閸嬫挻鎷呴崘顭戞闂佺硶鏅幏锟�